Maximilian Winter
Founder & General Partner at Harmonix | Pioneering the Future of Health
United States
Invests in
Sectors:
Locations:
Min Investment:
$250,000.00Max Investment:
$3,000,000.00Target Investment:
$1,000,000.00
Education
Lists including Maximilian
Investments
Attivare Therapeutics
Total Funding: $11M
Caresyntax
Total Funding: $150M
Loft Orbital Solutions Inc.
Total Funding: $17M
Sorcero
Total Funding: $5.7M
XCures
Total Funding: $13M
Scribe Biosciences
Total Funding: $4.5M
Atlas Space
Total Funding: $5M
Sana Health
Total Funding: $24M
Bioz
Total Funding: $52M
Paradromics
Total Funding: $90M
Trials.ai
Total Funding:
PathologyWatch
Total Funding:
Qu Biologics
Total Funding:
Rad.AI
Total Funding:
Auransa
Total Funding:
Juvena Therapeutics
Total Funding: $41M
Viscient Biosciences
Total Funding:
Volumetric Bio
Total Funding:
Abalone Bio
Total Funding: $150K
VastBiome
Total Funding:
Sensae
Total Funding:
Insilico Medicine
Total Funding: $390M
Prime Movers Lab Fund II
Total Funding:
SentiAR
Total Funding: $13M
Halo Industries
Total Funding: $80M
Tarana Wireless
Total Funding: $360M
Gen1e Lifesciences
Total Funding:
Nelumbo
Total Funding: $20M
Agroscience Capital
Total Funding:
Unlimited Tomorrow
Total Funding:
Edenworks
Total Funding:
Terramera
Total Funding:
Mathison
Total Funding: $31M
Momentus
Total Funding: $34M
Reitium
Total Funding:
Babylon Micro-Farms
Total Funding:
polySpectra
Total Funding:
Prime Movers Lab Fund I
Total Funding:
Partsium
Total Funding:
Cyborg Nest
Total Funding:
Dermasensor
Total Funding:
Amaz
Total Funding:
Precipoint
Total Funding:
Work Experience
2017
Founder & General Partner
2017
Harmonix is a pioneering venture capital firm investing in data-driven platform companies at the nexus of healthcare, life sciences, and critical infrastructure (deep tech). As key drivers of the fourth Industrial Revolution, engineering biology and computational methodologies are paving the way for a new epoch of commercialized scientific progress that enhances human and planetary well-being. The firm is on its third fund, comprising over 40 trailblazing companies that span AI-powered biotechnology, synthetic biology, healthcare, and critical infrastructure with national security implications. Notable breakthroughs include the first AI-designed drug to undergo clinical trials, a groundbreaking fully automated robotic cloud laboratory for synthetic biology research, and the inaugural rideshare satellite launch into orbit. Esteemed publications such as Bloomberg, BBC, Forbes, and Fortune have spotlighted the fund's portfolio companies for their transformative scientific achievements.
Member Board of Directors
2015
2021
Board Observer
2021